Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome

References

• Short RV. Steroids in the follicular fluid and the corpus luteum of the mare. A two cell type theory of ovarian steroid synthesis. J Endocrinol 1962; 24: 59–64
   PubMed Web of Science ®Google Scholar
• Ryan KJ, Petro F, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and theca cells. J Clin Endocrinol Metab 1968; 28: 355–8
   PubMed Web of Science ®Google Scholar
• Shoham Z, Mannaerts B, Insler V, et al. Induction of follicular growth using recombinant human follicle stimulating hormone in two volunteer women with hypogonadotrophic hypogonadism. Fertil Steril 1993; 59: 738–42
   PubMed Web of Science ®Google Scholar
• Jones GS, Garcia JE, Rosenwaks Z. The role of pituitary gonadotropins in follicular stimulation and oocyte maturation in the human. J Clin Endocrinol Metab 1984; 59: 178–80
   PubMed Web of Science ®Google Scholar
• Venturoli S, Orsini LF, Paradisi R, et al. Human urinary follicle stimulating hormone and human menopausal gonadotropin in induction of multiple follicle growth and ovulation. Fertil Steril 1986; 45: 30–5
   PubMedGoogle Scholar
• Martikainen H, Ronnberg L, Puistola U, et al. Comparison of the effects of follicle stimulating hormone and human menopausal gonadotropin on peripheral serum and follicular fluid hormones during ovarian stimulation. Fertil Steril 1986; 42: 317–20
   Google Scholar
• Bentick B, Shaw RW, Iffland CA, et al. A randomised comparative study of purified follicle-stimulating hormone and human menopausal gonadotropin after pituitary desensitisation with buserelin for superovulation and in vitro fertilisation. Fertil Steril 1988; 50: 79–84
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Insler V. Classification of anovulatory states. Ovulation in the Human, PG Crosignani, DS Mishell. Raven Press, London 1976; 211–6
   Google Scholar
• Shoham Z, Balen A, Patel A, et al. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypergonadotropic hypogonadism patients. Fertil Steril 1991; 56: 1048–53
   PubMed Web of Science ®Google Scholar
• Fox R. Ovarian response to purified FSH in infertile women with long-standing hypogonadotrophic hypogonadism. Austr NZ J Obstet Gynecol 1997; 37: 92–4
   PubMed Web of Science ®Google Scholar
• Santoro N, Filicori M, Crowley WT. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin releasing hormone. Endocr Rev 1986; 7: 11–23
   PubMed Web of Science ®Google Scholar
• Dufau ML, Veldhius J. Pathophysiological relationships between the biological and immunological activities of luteinizing hormone. Clinical Endocrinology and Metabolism, E Burger. Ballière, London 1987; 153
   Google Scholar
• Noci I, Biagiotti R, Maggi M, et al. Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation. Hum Reprod 1998; 13: 531–4
   PubMed Web of Science ®Google Scholar
• Hughes EG, Fedorkow DM, Daya S, et al. The routine use of gonadotropin-releasing hormone agonists for in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992; 48: 888–96
   Google Scholar
• Loumaye E, Engrand P, Howies CM, et al. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril 1997; 67: 889–99
   PubMed Web of Science ®Google Scholar
• Noci I, Borri P, Coccia ME, et al. Hormonal patterns, steroid receptors and morphological pictures of endometrium in hyperstimulated IVF cycles. Eur J Obstet Gynecol Reprod Biol 1997; 75: 215–20
   PubMedGoogle Scholar
• Develioglu OH, Cox B, Toner JP, et al. The value of basal serum follicle stimulating hormone, luteinizing hormone and oestradiol concentrations following pituitary down-regulation in predicting ovarian response to stimulation with highly purified follicle stimulating hormone. Hum Reprod 1999; 14: 1168–74
   PubMed Web of Science ®Google Scholar
• Fleming HR, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998; 13: 1788–92
   PubMed Web of Science ®Google Scholar
• Vicdan K, Isik AZ. Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation. Hum Reprod 1999; 14: 863–4
   PubMedGoogle Scholar
• Meniru GI, Craft IL. Utilization of retrieved oocytes as an index of the efficiency of superovulation strategies for in vitro fertilization treatment. Hum Reprod 1997; 12: 2129–32
   PubMed Web of Science ®Google Scholar
• Milad MP, Ball GD, Erickson LD, et al. A successful assisted reproductive technology satellite program. Fertil Steril 1993; 60: 716–9
   PubMedGoogle Scholar
• Edwards RG, Lobo RA, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996; 11: 917–9
   PubMed Web of Science ®Google Scholar
• Lu PY, Chen ALJ, Atkinson EJ, et al. Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility. Fertil Steril 1996; 65: 583–7
   PubMed Web of Science ®Google Scholar
• Edwards RG, Lobo RA, Bouchard P. Why delay the obvious need for milder forms of ovarian stimulation?. Hum Reprod 1997; 12: 399–401
   PubMedGoogle Scholar
• Hughes EG, Collins JA, Gunby J. A randomized controlled trial of three low-dose gonadotrophin protocols for unexplained infertility. Hum Reprod 1998; 13: 1527–31
   PubMedGoogle Scholar
• Out HJ, Lindenber S, Mikkelsen AL, et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999; 14: 622–7
   PubMed Web of Science ®Google Scholar
• Rongières-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in in vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999; 14: 683–8
   PubMed Web of Science ®Google Scholar